Cargando…
BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
Altering the natural history of acute myeloid leukemia (AML) in unfit and older patients has proved a highly challenging hurdle, despite several decades of concerted clinical trial effort. The arrival of venetoclax (VEN) to the clinical stage represents the most important therapeutic advance to date...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256369/ https://www.ncbi.nlm.nih.gov/pubmed/37304937 http://dx.doi.org/10.1097/HS9.0000000000000912 |